Update on Exhaled Nitric Oxide in Clinical Practice.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26836891.
- Also identified by DOI 10.1016/j.chest.2015.11.020.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Asthma is characterized by chronic airway inflammation. Fractional exhaled nitric oxide (Feno) has emerged as a marker of T-helper cell type 2-mediated allergic airway inflammation. Recent studies suggest a role for Feno testing as a point-of-care tool in the management of patients with asthma. This Topics in Practice Management article reviews current coverage and reimbursement issues related to Feno testing and provides an overview of pertinent recent studies.
Medical subject headings
- Asthma
- Breath Tests
- Nitric Oxide